美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Bicara Therapeutics

23.90

-0.4900-2.01%

盤後：23.900.00000.00%19:30 EDT

成交量：49.64萬

成交額：1,202.92萬

市值：15.82億

市盈率：-7.69

高：25.56

開：24.73

低：23.77

收：24.39

52周最高：30.99

52周最低：10.30

股本：6,617.29萬

流通股本：5,230.21萬

量比：1.00

換手率：0.95%

股息：- -

股息率：- -

每股收益(TTM):-3.1097

每股收益(LYR):-2.5230

淨資產收益率：-41.01%

總資產收益率：-26.14%

市淨率：3.37

市盈率(LYR):-9.47

資料載入中...

總覽公司新聞資訊公告

美國研究綜述-卡迪納爾健康、盧門圖姆控股、公共倉儲

Bicara Therapeutics發布2026年第二季度進展，宣佈戰略領導層變動，開啓執行與增長新篇章

Bicara Therapeutics公司：1500毫克Ficerafusp Alfa聯合帕博利珠單抗在1L R/M HPV陰性HNSCC中顯示31%的三年總生存率

Bicara Therapeutics公布1B期研究結果：展現深度、持久的應答與良好的耐受性安全性特徵

美國研究綜述-愛彼迎、HII、特斯拉

Biocon董事長基蘭·馬祖姆達爾-肖制定五年繼任計劃，指定侄女為繼任者

Biocon董事長基蘭·馬祖姆達爾-肖確定繼任人選，這家印度製藥公司正籌劃領導層交接

異動解讀 | 啓動關鍵性試驗第三階段，Bicara Therapeutics盤中大漲5.68%

異動解讀 | Bicara Therapeutics啓動關鍵性試驗第三階段，股價盤前大漲5.55%

Bicara Therapeutics啓動Fortifi-Hn01關鍵性試驗第三階段中期分析預計2027年中進行

Bicara Therapeutics超額認購公開發行圓滿收官，承銷商全額行使額外購股權

BUZZ-Bicara Therapeutics 募資 1.5 億美元后股價上漲

Bicara Therapeutics宣佈1.5億美元普通股及預付認股權證公開發行定價

Ficerafusp Alfa 2000毫克Q2w方案在1L R/M HPV陰性頭頸鱗癌中展現深度持久療效並支持開發更低頻給藥方案

Bicara Therapeutics計劃開發Ficerafusp Alfa的負荷劑量與三周一次維持方案，待監管審批

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BCAX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":23.9,"timestamp":1787342400000,"preClose":24.39,"halted":0,"volume":496353,"hourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020090200902009102,"floatShares":52302133,"shares":66172934,"eps":-3.109661,"marketStatus":"休市中","change":-0.49,"latestTime":"08-21 16:00:00 EDT","open":24.73,"high":25.555,"low":23.77,"amount":12029223.159954,"amplitude":0.073186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":24.39,"preHourTrading":{"tag":"盘前","latestPrice":24.39,"preClose":24.39,"latestTime":"08:45 EDT","volume":3,"amount":73.17,"timestamp":1787316356497,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0006487493527585,"impliedVol":0.4166,"impliedVolPercentile":0.6016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":52302133,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":1.0006487493527585,"shares":66172934,"dividePrice":0,"high":25.555,"amplitude":0.073186,"preClose":24.39,"low":23.77,"week52Low":10.295,"pbRate":"3.37","week52High":30.99,"institutionHeld":0,"latestPrice":23.9,"eps":-3.109661,"divideRate":0,"volume":496353,"delay":0,"ttmEps":-3.109661,"open":24.73,"prevYearClose":16.83,"prevWeekClose":24.28,"prevMonthClose":27.1,"prevQuarterClose":29.69,"fiveDayClose":24.28,"twentyDayClose":27.02,"sixtyDayClose":21.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3125,"buy":0.5,"hold":0.1875,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":16,"updateTime":1787112000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-08-21","current":-7.685725,"percent":0.592975,"low":-22.704836,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"high":-5.144536,"avg":-10.510848,"sd":4.129805,"marketCap":1613957860},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860}],"updateTime":1787525108377},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658927621","title":"美國研究綜述-卡迪納爾健康、盧門圖姆控股、公共倉儲","url":"https://stock-news.laohu8.com/highlight/detail?id=2658927621","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658927621?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 16:08","pubTimestamp":1786522123,"startTime":"0","endTime":"0","summary":"美国研究综述-卡迪纳尔健康、卢门图姆控股、公共仓储路透8月12日-周三，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括卡迪纳尔健康、卢门图姆控股和公共仓储。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4S4490GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTR","BCAX","PSA","ACVA","LBRX","BBIO","USFD","CAVA","MDLN","LEGN","MNST","JBIO","MIDD","SR","WELL","EGGY","TXG","TGT","LOW","ANF","MRCY","LPTH","JAZZ","REIT","AMBQ","RPD","COAG","NTRA","UMAC","LENZ","CVS","CAH","PNW","HD","URBN","BLCK","GAP","CRCL","NEMG","CUBE","HLIO","CANC","MAA","ACM","NEM","CRWV","LITE","EXR","FLUT","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189357607","title":"Bicara Therapeutics發布2026年第二季度進展，宣佈戰略領導層變動，開啓執行與增長新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1189357607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189357607?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447875,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics今日披露其2026年第二季度的业务进展，并同步宣布一系列战略性的领导层调整。此举标志着公司正迈入一个全新的执行与增长阶段。这些变动旨在优化管理架构，为下一阶段的战略推进奠定坚实基础。公司方面表示，此次领导层的过渡是基于对未来发展的深思熟虑，旨在更高效地驱动核心项目，并把握市场机遇。通过引入新的领导视角与经验，Bicara Therapeutics正蓄势待发，准备在充满活力的生物技术领域加速前行，致力于为患者带来突破性的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168800830","title":"Bicara Therapeutics公司：1500毫克Ficerafusp Alfa聯合帕博利珠單抗在1L R/M HPV陰性HNSCC中顯示31%的三年總生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=1168800830","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168800830?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 05:09","pubTimestamp":1779397760,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics公司公布的数据显示，其1500毫克剂量的Ficerafusp Alfa联合帕博利珠单抗，在一线治疗复发/转移性人乳头瘤病毒阴性头颈鳞状细胞癌患者中，取得了31%的三年总生存率结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150998880","title":"Bicara Therapeutics公布1B期研究結果：展現深度、持久的應答與良好的耐受性安全性特徵","url":"https://stock-news.laohu8.com/highlight/detail?id=1150998880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150998880?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 05:09","pubTimestamp":1779397753,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc 公布的最新1B期临床研究数据揭示，其试验性疗法展现出深度且持久的治疗应答，同时具备耐受性良好的安全性特征。该研究结果进一步支持了该疗法的临床开发潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634403179","title":"美國研究綜述-愛彼迎、HII、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2634403179","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634403179?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 15:29","pubTimestamp":1778484590,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、HII、特斯拉路透5月11日 - 周一，华尔街证券分析师下调了多家美国上市公司的评级和目标股价，其中包括爱彼迎、HII和特斯拉。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4T41O0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDG","HII","AGL","LOAR","FRDU","ABNG","AMDS","BWA","HUBS","AMUU","ANIP","ALB","AMDY","F","CWH","AMYY","FERG","CVS","ATLC","AZTA","THRM","AMPH","FIS","DASH","GNTX","BILL","JBIO","TECH","BCAX","GFS","CAR","GM","IBP","BAM","ESE","GT","ABNB","ARXS","INTU","LEA","LNTH","AMDW","DAMD","FRDD","HWM","AVTX","HTZ","CGON","AMD","DAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633617992","title":"Biocon董事長基蘭·馬祖姆達爾-肖制定五年繼任計劃，指定侄女為繼任者","url":"https://stock-news.laohu8.com/highlight/detail?id=2633617992","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633617992?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 14:46","pubTimestamp":1777963591,"startTime":"0","endTime":"0","summary":"更新版 2-Biocon董事长基兰·马祖姆达尔-肖制定五年继任计划，指定侄女为继任者补充了评论、细节和背景信息Rishika Sadam. 路透5月5日 - Biocon BION.NS 创始人兼董事长基兰·马祖姆达尔-肖周二表示，她计划在未来五年内分阶段进行领导层交接，其侄女克莱尔·马祖姆达尔预计最终将接任董事长一职。“只要我们持有Biocon的大量股份，我就想确保家族的传承能够延续，”马祖姆达尔-肖表示，并补充说她的家族成员一直担任该公司董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4S41I0DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633399470","title":"Biocon董事長基蘭·馬祖姆達爾-肖確定繼任人選，這家印度製藥公司正籌劃領導層交接","url":"https://stock-news.laohu8.com/highlight/detail?id=2633399470","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633399470?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 14:29","pubTimestamp":1777962582,"startTime":"0","endTime":"0","summary":"Biocon董事长基兰·马祖姆达尔-肖确定继任人选，这家印度制药公司正筹划领导层交接\n路透5月5日 - Biocon创始人基兰·马祖姆达尔-肖向路透表示，她计划在未来五年内逐步完成领导层交接，其侄女克莱尔·马祖姆达尔预计将分阶段接任董事长一职。该继任计划最初由商业杂志《财富印度》在对马祖姆达尔-肖的采访中报道 (link)。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4S41I0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111684845","title":"異動解讀 | 啓動關鍵性試驗第三階段，Bicara Therapeutics盤中大漲5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111684845","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111684845?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:15","pubTimestamp":1774880121,"startTime":"0","endTime":"0","summary":"消息面上，公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性，这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注，若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择，并可能为公司带来重要的商业机会。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154155522","title":"異動解讀 | Bicara Therapeutics啓動關鍵性試驗第三階段，股價盤前大漲5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154155522","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154155522?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:36","pubTimestamp":1774870598,"startTime":"0","endTime":"0","summary":"消息面上，公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性，这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注，若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择，并可能为公司带来重要的商业机会。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178506877","title":"Bicara Therapeutics啓動Fortifi-Hn01關鍵性試驗第三階段 中期分析預計2027年中進行","url":"https://stock-news.laohu8.com/highlight/detail?id=1178506877","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178506877?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:35","pubTimestamp":1774870518,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics（股票代码：BCAX）已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性。\n根据公司公布的时间表，该项试验的中期分析预计将于2027年中期完成。这一关键节点将为后续临床决策提供重要数据支持，并可能影响该疗法的最终审批路径。\nFortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注。若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162640845","title":"Bicara Therapeutics超額認購公開發行圓滿收官，承銷商全額行使額外購股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1162640845","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162640845?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 05:30","pubTimestamp":1772141409,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics宣布其公开发行已正式完成，本次发行获得超额认购。承销商已全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614082484","title":"BUZZ-Bicara Therapeutics 募資 1.5 億美元后股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082484","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082484?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 21:02","pubTimestamp":1772024573,"startTime":"0","endTime":"0","summary":"BUZZ-Bicara Therapeutics 募资 1.5 亿美元后股价上涨2月25日 - ** Bicara Therapeutics BCAX.O股价在隔夜1.5亿美元的后续交易中盘前上涨4.2%，报16.93美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4S3ZL17J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LU2089284900.SGD","LU1244550221.USD","LU1989772840.SGD","LU2089283258.USD","LU0106831901.USD","LU0234570918.USD","LU1162221912.USD","LU0106261372.USD","BK4139","BK4516","LU1791710582.SGD","BK4127","LU2271345857.HKD","LU1732799900.SGD","LU0795875169.SGD","LU1732800096.USD","LU0006306889.USD","LU1791710400.SGD","LU2023251221.USD","LU0912757837.SGD","LU1720051017.SGD","IE00BZ1G4Q59.USD","BK4504","LU1548497426.USD","LU2028103732.USD","LU2347655156.SGD","BCAX","LU0557290698.USD","LU0267386448.USD","LU2111349929.HKD","BK4581","LU1989772923.USD","LU2133065610.SGD","LU0320765646.SGD","LU2357305700.SGD","LU0528227936.USD","LU0795875086.SGD","LU1720051108.HKD","LU0314104364.USD","LU1244550577.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","LU1244550494.USD","LU0882574139.USD","BK4585","BK4534","BK4588","LU0098860793.USD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134029809","title":"Bicara Therapeutics宣佈1.5億美元普通股及預付認股權證公開發行定價","url":"https://stock-news.laohu8.com/highlight/detail?id=1134029809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134029809?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992810,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics已正式确定其1.5亿美元普通股及预付认股权证的公开发行价格。此次融资将支持公司推进其肿瘤治疗产品管线的临床开发。市场密切关注此次发行对公司未来发展的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132051680","title":"Ficerafusp Alfa 2000毫克Q2w方案在1L R/M HPV陰性頭頸鱗癌中展現深度持久療效 並支持開發更低頻給藥方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1132051680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132051680?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536793,"startTime":"0","endTime":"0","summary":"Ficerafusp Alfa采用2000毫克每两周给药方案，在治疗一线复发/转移性HPV阴性头颈部鳞状细胞癌患者时，展现出深度且持久的肿瘤缓解效果。该积极数据为进一步开发给药频率更低的治疗方案提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109954715","title":"Bicara Therapeutics計劃開發Ficerafusp Alfa的負荷劑量與三周一次維持方案，待監管審批","url":"https://stock-news.laohu8.com/highlight/detail?id=1109954715","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109954715?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536792,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. 宣布，公司计划为其在研药物Ficerafusp Alfa开发一种负荷剂量联合每三周一次维持给药的用药方案。该开发计划的推进，将取决于与监管机构达成一致意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}